In that study the incidence of fatal thromboembolic events was higher in patients receiving epoetin alfa than in those receiving placebo (see section 5.1).
92 fataalsete trombembooliliste tüsistusjuhtude arv võrreldes platseebot saavate patsientidega suurem patsientidel, kes said alfaepoetiini (vt lõik 5. 1).